134 results about "A549 cell" patented technology

The invention relates to lactobacillus reuteri HC1602 as well as a fungicide and application thereof, and belongs to the technical field of microorganisms. The lactobacillus reuteri HC1602 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.26890, the preservation date is March 23, 2023, and the address of the preservation institution is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The invention further provides application of the lactobacillus reuteri HC1602 in preparation of products for inhibiting and preventing respiratory syncytial viruses and application of the lactobacillus reuteri HC1602 in preparation of products for reducing cholesterol in blood. The lactobacillus reuteri HC1602 provided by the invention can be used for effectively inhibiting the invasion of RSV (Respiratory Syndrome Virus) to A549 lung cells and improving the survival rate of the A549 cells.

The invention discloses an SOD2 knockout cell line and application of the SOD2 knockout cell line in anti-poxvirus, and relates to the technical field of antiviral research. According to the invention, sgRNA of targeted superoxide dismutase 2 (SOD2) is designed, the sequence of the sgRNA is shown as SEQ ID NO.1-SEQ ID NO.2, then a stable SOD2 knockout human-derived non-small cell lung cancer A549 cell line is established by combining CRISPR / Cas9 gene editing with a lentiviral vector delivery technology, single-cell cloning is obtained through multiple rounds of puromycin screening, and the SOD2 gene knockout A549 cell strain is successfully constructed. Vaccinia virus Tian Tan strain infection shows that the number of plaques of SOD2 knockout cells is obviously greater than that of the plaques (about 2.3 times) of normal cell infection, and the plaques are relatively large, so that fine SOD2 has the effect of limiting intercellular transmission of poxvirus. The invention lays a foundation for research and preparation of antiviral drugs.

The invention relates to a 5, 9-di-tert-butyl naphtho-indolizine phenothiazine compound as well as a preparation method and medical application thereof. The compound is efficiently synthesized through Ullmann coupling and palladium-catalyzed intramolecular arylation reaction. In-vitro anti-tumor activity research shows that the compound has remarkable selective inhibitory activity on various human tumor cell lines, and particularly, the inhibitory effect on non-small cell lung cancer A549 cells (IC50 = 0.21 mu M) is improved by two orders of magnitude compared with that of cis-platinum; iC50 (half maximal inhibitory concentration) of other cell lines are as follows: 1.26 mu M of prostate cancer PC-3 cells, 6.78 mu M of liver cancer HepG2 cells, 7.99 mu M of cervical cancer Hela cells and 25.46 mu M of breast cancer MCF-7 cells. Preliminary toxicity experiments prove that the compound has the characteristic of low cytotoxicity. The compound can be used as a novel high-efficiency low-toxicity anti-tumor lead compound, and provides an important structural basis for the development of anti-cancer drugs.

The present invention relates to the technical field of traditional Chinese medicine. Disclosed is use of zedoarondiol in the preparation of a drug for preventing, treating, and inhibiting lung cancer. It has been discovered that zedoarondiol can effectively induce apoptosis of A549 cells, inhibit the growth of non-small cell lung cancer, significantly inhibit the migration of A549 cells, hinder the development of non-small cell lung cancer, and simultaneously inhibit tumor growth. The present invention provides new use of zedoarondiol, expanding the medical application of zedoarondiol and offering a new technical means for lung cancer treatment.

The invention discloses a polyketone compound derived from actinomycetes as well as a preparation method and application thereof, and relates to the technical field of microbial natural product mining and biological medicine, and the key point of the technical scheme is that the invention discloses a novel polyketone compound Strepactone derived from actinomycetes Streptomyces sp. DP0001, and the molecular formula of the novel polyketone compound Strepactone is C25H38O5. The compound is obtained through strain fermentation, ethyl acetate extraction and multi-step chromatographic purification, and the structure is identified through ESI-MS, 1H NMR and 13C NMR. Experiments show that Strepactone has an inhibition effect on staphylococcus aureus and methicillin-resistant staphylococcus aureus and has remarkable inhibition activity on human non-small cell lung cancer A549 cells, the half inhibitory concentration IC50 of the Strepactone is 5.36 mu M, and the Strepactone has no obvious cytotoxic activity on human embryo kidney cells 293T cells at the concentration of 30 mu M. The compound provided by the invention can be used for preparing anti-drug-resistant bacteria drugs and anti-human non-small cell lung cancer drugs, and also provides a structural basis for the development of novel antibacterial and anti-tumor leading drugs.

The invention discloses application of a TIMM10 gene as a target spot in resisting influenza A virus, and belongs to the technical field of biological medicine. Specifically, TIMM10 gene knock-down is carried out on A549 cells, and it is found that in the cells with knocked-down TIMM10, expression of main protein hemagglutinin and nucleoprotein of influenza viruses is remarkably improved, and virus RNA and virus titer in supernate are also remarkably increased; overexpression of TIMM10 in A549 cells inhibits replication and infectivity of IAV in the cells. A further in-vivo experiment is carried out through a TIMM10 whole body knockout heterozygote mouse, and a result shows that the lung of the TIMM10 heterozygote mouse shows more serious pulmonary infection, including pulmonary hemorrhage and increased inflammatory cell infiltration. Based on the effect of TIMM10 in the influenza virus infection process, the invention provides a new therapeutic target, and provides a new thought and direction for developing a therapeutic strategy for IAV in the future.

The application belongs to the technical field of medical preparations. The application provides a modified quantum dot Chlorella polyhedral composite material for radiotherapy sensitization, a preparation method and application. The preparation method comprises the following steps: preparing a doped tungsten-chromium gallate quantum dot with a chemical formula of Zn 0.98 Ga2O4:W 0.02 6+ ,Cr 0.02 3+ ; then, the doped tungsten-chromium gallate quantum dot is modified by amination, and then modified by a polysaccharide mixture composed of alpha-maltose, cellulose and sodium alginate; finally, the doped tungsten-chromium gallate quantum dot is co-incubated with Chlorella polyhedral to obtain the modified quantum dot Chlorella polyhedral composite material. The modified quantum dot can enter Chlorella polyhedral in a large amount, and the modified quantum dot in the material obtained by the application is not easy to overflow or fall off, and is easy to preserve, compared with the prior art. Meanwhile, the material obtained by the application has a very high killing effect on CT26 cells and A549 cells at a very low dose, and the cell apoptosis rates of the two kinds of cells are both more than 80%. Therefore, the application has a high industrial application prospect.

The invention discloses a synthetic method of a C1-triazole oridonin derivative and an anti-tumor application of the C1-triazole oridonin derivative. The invention provides a synthetic method of the C1-triazole oridonin derivative, which comprises the following steps: carrying out four-step reaction to obtain an oridonin analogue containing an azide group at the C1 site, and catalyzing by cuprous iodide to obtain the C1-triazole oridonin derivative with the azide group at the C1 site, thereby obtaining the C1-triazole oridonin derivative with the azide group at the C1 site and the oridonin analogue with the azide group at the C1 site. According to the method, alkyne compounds containing different substituent groups react with C1-triazole oridonin to synthesize the C1-triazole oridonin derivative, the method is mild in condition and rapid in reaction, large-scale preparation of the C1-triazole oridonin derivative can be achieved, and the method is suitable for large-scale production of the C1-triazole oridonin derivative. Meanwhile, the C1-triazole oridonin derivative synthesized by the invention can be used for effectively inhibiting the proliferation activity of tumor cells and has a relatively good inhibition effect on MCF-7 cells and A549 cells.

The present application provides the use of raltitrexed in the manufacture of a medicament for the treatment of diseases caused by adenovirus infection, including but not limited to respiratory tract infection, gastrointestinal infection and keratitis caused by adenovirus. When raltitrexed was tested for its anti-adenovirus activity at the cellular level, using a viral infection dose of 100 TCID50, the viral infectivity was determined on a human non-small cell lung cancer cell line (A549 cell) model, and the results showed that raltitrexed had a significant inhibitory effect on adenovirus, with an EC 50 = 8.98 nM, a CC 50 > 187.5 nM, and it was found that it had a significant inhibitory effect on the entry of the virus into the cell; and in the hDSG2 mouse model, a significant inhibitory effect of raltitrexed on viral replication was also observed. Therefore, raltitrexed can be used to treat diseases caused by adenovirus infection.

The present application relates to the technical field of medicine, in particular to the application of gansix triol A in the preparation of a drug for treating gastric cancer and / or non-small cell lung cancer, gansix triol A plays an anti-gastric cancer role by selectively inhibiting the proliferation of gastric cancer MGC-803 cells and inhibiting angiogenesis, the mechanism involves inhibiting the VEGF / VEGFR2 signal pathway and inducing cell apoptosis; the mechanism of gansix triol A in inhibiting the VEGF / VEGFR2 signal pathway is similar to that of bevacizumab; gansix triol A plays an anti-non-small cell lung cancer role by selectively inhibiting the proliferation of non-small cell lung cancer A549 cells, the mechanism involves inhibiting the MAPK / ERK signal pathway and inducing cell apoptosis. The present application finds that the cytotoxic activity of gansix triol A on MGC-803 cells and A549 cells is significantly stronger than that of tanshinone IIA; gansix triol A has an anti-tumor effect of "one drug with double targets, double inhibition" and "high efficiency and low toxicity".

The invention provides an application of an ANGPT2 monoclonal antibody in preparation of a medicine for treating non-small cell lung cancer of a subject subjected to heavy ion treatment. Research results show that the promotion effect of the combined treatment of the nevapsumab and the heavy ion irradiation on ANGPT2 overexpression A549 cell cycle arrest and cell apoptosis rate and the inhibition effect on cell invasion, migration and clone forming ability are obviously better than those of the single treatment of the nevapsumab and the heavy ion irradiation. In a nude mouse transplantation tumor model, the inhibition effect of the combined treatment on the growth of ANGPT2 overexpression A549 cell transplantation tumor is more obvious than that of the single treatment of nevapsumab and heavy ion irradiation, and the negative influence on the physiological state of a host is smaller. A new strategy is provided for clinical treatment of the non-small cell lung cancer, and it is indicated that combined application of heavy ion treatment and ANGPT2 monoclonal antibody is expected to improve the treatment effect, prolong the lifetime of a patient and reduce treatment-related side effects, so that the life quality of the patient is remarkably improved.

The invention belongs to the field of biology, and relates to a broad-spectrum monoclonal antibody aiming at avian influenza virus M1 protein and application of the broad-spectrum monoclonal antibody, the monoclonal antibody has specific reaction with A549 cells infected by avian influenza, has no specific reaction with Newcastle disease virus, duck tembusu virus, goose astrovirus and infectious laryngitis virus, has good specificity, and can be used for preparing the broad-spectrum monoclonal antibody. The 5G9 monoclonal antibody has good reactivity with A549 cells infected by H1-H11 subtype AIV, has good broad spectrum, can be used for detecting M1 protein sub-localization after the AIV infected cells are detected by using the 5G9 monoclonal antibody, and can be used for indicating the infection process of the AIV.

The present application provides an indole derivative and a preparation method and application thereof. The preparation method comprises the following steps: dissolving copper acetate and triethylamine in isopropyl alcohol, stirring until completely dissolved to obtain a reaction medium; adding 5-bromo indigo and indole into the reaction medium, fully stirring at room temperature until the reaction is completely converted; removing the reaction solvent by distillation to obtain a crude product, purifying and recrystallizing to obtain a high-purity solid powder of the indole derivative. The indole derivative has a significant inhibitory effect on tyrosinase, melanin production and transfer; has high antioxidant capacity for scavenging intracellular active oxygen free radicals; through the mechanisms of affecting the membrane potential of mitochondria, activating the related apoptosis signaling pathway and promoting the expression of apoptosis proteins, etc., the A549 cell is prompted to enter the apoptosis program, thereby providing a new potential strategy and research direction for the apoptosis regulation of tumor cells, and having important research value and application prospect.

The present invention relates to a mononitroisosorbide derivative, its preparation method, and application. The derivative has the following structure: #imgabs0#, wherein R is one of the following structures: #imgabs1#. The mononitroisosorbide derivative is prepared by reacting 5-isosorbide mononitrate with an acyl chloride (sulfonyl chloride) compound in the presence of triethylamine and a catalyst, 4-dimethylaminopyridine. The mononitroisosorbide derivative exhibits excellent anti-tumor activity. Compared to existing technologies, the present invention designs and synthesizes multiple compounds with novel structures, among which ZM533 exhibits moderate anti-tumor activity against the A549 cell line and is expected to be used in the preparation of anti-lung cancer drugs.

The invention discloses a phenoxazine skeleton-containing drug small molecule and application thereof, and belongs to the technical field of synthesis of heterocyclic compounds and antitumor drugs, the phenoxazine skeleton-containing drug small molecule has an inhibition effect on HepG2 and A549, a phenoxazine derivative 7c with the third site connected with a methoxy group at the tail end of a phenoxazine structure benzene ring has a better overall effect, and the phenoxazine skeleton-containing drug small molecule can be applied to preparation of antitumor drugs. The inhibition rates of the compound on HepG2 and A549 are respectively 87.67% and 94.23%. 7g of the phenoxazine derivative of which the methyl ester structure is connected to the third site of the phenoxazine structure only has an obvious effect on A549, and the inhibition rate in A549 cells is 96.00%.

The invention provides a construction method of a non-small cell lung cancer histone H1.3 arginine methylation point mutation cell model. The construction method comprises the following steps: designing mutation primers H1.3 R80A-F and H1.3 R80A-R; the method comprises the following steps: by taking a pCDH-HA-H1.3-Flag plasmid as a template, carrying out PCR (Polymerase Chain Reaction) amplification by adopting a mutation primer, digesting a product by DMT enzyme, and converting a competent cell to obtain a mutant plasmid; and co-transfecting the mutant plasmid and a helper plasmid to a packaging cell, collecting a virus solution, filtering, infecting an A549 cell, adding Polybrene to assist infection, culturing, and screening a stably transfected cell strain by using puromycin to obtain the recombinant plasmid. The invention also provides application of the mutant cell model obtained by the construction method. According to the invention, the blank of histone H1.3 methylation research is filled, the 80th arginine is clear as a core modification site, and the established model provides a new tool for lung cancer mechanism research and drug research and development.

The invention relates to a sesquiterpenoid glycoside compound in Atractylodes lancea, and a preparation method and application thereof. The invention belongs to the technical field of medicines, and relates to a method for extracting and separating a sesquiterpenoid glycoside compound (1S, 5S, 7R, 10S)-10-hydroxy-deoxy split-ring atractylodes macrocephala delta-lactone-11-O-beta-D-glucopyranoside from rhizome of Atractylodes lancea by using normal phase silica gel, reverse phase silica gel, preparative high performance liquid chromatography and other technologies. In-vitro anti-tumor activity screening experiments show that the compound has good anti-tumor activity, including obvious inhibition effects on human lung cancer cells A549, human cervical cancer cells Hela and human liver cancer cells HepG-2. Therefore, the sesquiterpenoid glycoside compound has a prospect of being developed into antitumor drugs.

The invention discloses a nucleotide for inhibiting expression of ILKAP (Interleukin-7-Kinase Associated Protein) related circular RNA (Ribonucleic Acid) and application of the nucleotide, and the nucleotide is characterized in that the nucleotide sequence is CGUCAGUACUCGGGUUUCA, and the expression level of hsacirc0001116 can be specifically and obviously reduced. Experimental results prove that the nucleic acid molecule can effectively interfere with the expression of hsacirc0001116 in human non-small cell lung cancer A549 cells, and can significantly inhibit the survival of lung cancer cells. In addition, when the nucleic acid molecule is combined with an existing antitumor drug for use, a synergistic treatment effect can be generated.

The present invention discloses the preparation and application of an anti-Pseudomonas aeruginosa PcrV antibody. The present invention proves through experiments that the PcrV antibody can specifically bind to the PcrV antigen, has a neutralizing effect on the lysis of A549 cells by PcrV, and also has the ability to neutralize the lysis of rabbit red blood cells mediated by PcrV, and has a preventive / therapeutic effect on systemic infection and acute pneumonia.

The invention discloses a polyclonal antibody targeting a human CPNE7 variable splicing isomer and application of the polyclonal antibody, and belongs to the technical field of biological medicine. The antigen epitope 'KYKQKRRSYKN' (SEQ ID NO.1) capable of being targeted by the polyclonal antibody provided by the invention is positioned in a common conserved region of all main isomers of CPNE7, and a variable splicing region is not involved. The titer of the obtained antibody serum is as high as 1: 32,000, which indicates that the antibody has extremely high immunoreactivity and sensitivity and can be used for detecting trace proteins. The antibody disclosed by the invention can be used for effectively identifying GST-CPNE7 fusion protein expressed by a prokaryotic system and CPNE7-FL and CPNE7-S protein overexpressed in an eukaryotic system (A549 cells), and the applicability of the antibody in various experimental systems is proved. Therefore, the blank in the prior art can be filled, and a core tool is provided for research of the CPNE7 in the fields of tumor biology, diagnosis and treatment.

The present invention belongs to the field of biomedical technologies, and particularly relates to the application of pyruvate in the preparation of a drug for enhancing the efficacy of lung cancer chemotherapy. The present invention provides a novel drug for treating lung cancer, namely Compound I obtained by structurally modifying sodium pyruvate. Experimental results show that this compound can significantly inhibit the proliferation of lung cancer cells A549 in mice, and at the same time has an inhibitory effect on the growth of human lung cancer A549 cell xenografts in nude mice, expanding the therapeutic potential of existing drugs and providing new treatment options for lung cancer patients. Its high efficiency in treating lung cancer is of great significance in improving the treatment effect and reducing the burden on patients.

This invention provides the application of apatinib in the preparation of antiviral drugs, specifically involving the application of the anticancer drug apatinib in inhibiting the replication of Hantanensis virus (HTNV) and Chikungunya virus (CHIKV). Apatinib can significantly inhibit HTNV replication and reduce viral titers at the cellular level. Experiments have shown that after treatment with apatinib, the expression levels of viral structural proteins, the nucleic acid levels of HTNV, and the viral titers in the cell culture supernatant were significantly reduced in HTNV-infected A549 cells, while the drug exhibited low cytotoxicity. Furthermore, apatinib can also inhibit CHIKV replication. This invention provides a novel anti-HTNV candidate drug and offers insights for the rapid development of antiviral drugs.

The invention discloses a nucleotide for targeted degradation of newly found reverse shear RNA ts-TIMP2 and application of the nucleotide, and is characterized in that the nucleotide achieves the effect of inhibiting lung cancer by inhibiting ts-TIMP2 mRNA without influencing normal cells, and the sequence of the nucleotide is CAUGCAGUGAUCAGGGCCdTdT and a complementary sequence GGCCCUGAUCACUGCAAUGdTdT thereof. The oligonucleotide disclosed by the invention can degrade ts-TIMP2 in a targeted manner, inhibits A549 cell proliferation under the condition of not influencing normal cell 16HBE, and can improve the anti-tumor effect by being combined with an anti-tumor drug inorganic arsenic for treatment.

The invention discloses a euphorbia helioscopia seed extract as well as a preparation method and application thereof in preparation of an anti-lung cancer medicine, and belongs to the field of biological medicines. The preparation method comprises the following steps: performing vortex extraction, centrifugation and concentration on a methanol extracting solution to prepare a euphorbia helioscopia seed extract; wide targeted metabonomics research results show that chemical components of the euphorbia helioscopia seed extract and chemical components of the euphorbia helioscopia whole herb extract are remarkably different. Experimental results show that the euphorbia helioscopia seed extract provided by the invention has strong toxicity to lung cancer A549 cells, has a remarkable inhibition effect on EMT generation and invasion and metastasis capacities in the A549 cells induced by TGF-beta1, and can be used for preparing medicines for resisting lung cancer. The invention provides technical support for development of the euphorbia helioscopia seed extract as a novel anti-lung cancer drug, lays a foundation for full utilization of euphorbia helioscopia seed resources, and has a wide application prospect.

The invention belongs to the technical field of gene engineering and biological medicine, and particularly relates to a biological material for inhibiting IDE gene expression and application of the biological material in anti-influenza virus. Researches find that specific inhibition of expression of the IDE gene can significantly inhibit infection of influenza viruses, especially H13N2 subtype influenza viruses. Specifically, the research finds that the mRNA expression level of the NP gene of the H13N2 subtype influenza virus in the A549 cell line for specifically inhibiting the IDE gene expression and the expression level of the PB2 protein are obviously reduced; meanwhile, the virus titer after the H13N2 subtype influenza virus infects the A549 cell line specifically inhibiting IDE gene expression is also obviously lower than that of a control group. The invention proves that the infection of the H13N2 subtype influenza virus can be obviously inhibited by specifically inhibiting the expression of the IDE gene, and a new thought is provided for resisting influenza virus infection, so that the method has a good practical application value.

The invention belongs to the technical field of organic synthesis and medicinal chemistry, and particularly relates to a synthesis method of a novel polycyclic aromatic hydrocarbon derivate 2, 6-di-tert-butyl pyrene and indolizine phenothiazine compound and application of the compound in the aspect of anti-cancer drugs. The synthesis process is simple and convenient, conditions are mild, and the yield is ideal. Pharmacodynamic evaluation shows that the compound shows strong inhibitory activity on various human cancer cell lines, and the IC50 values are respectively cervical cancer Hela cells (0.17 mu M), lung cancer A549 cells (0.3 mu M), prostatic cancer PC-3 cells (0.42 mu M) and liver cancer HepG2 cells (10.79 mu M), which are respectively reduced by 109 times, 173 times, 35 times and 1.8 times compared with positive control drug cis-platinum. In addition to efficiently inhibiting cancer cells, the compound has low toxicity to normal cells, meets the basic requirements of excellent anti-cancer drugs, and shows important application value and potential in the field of research and development of novel anti-cancer drugs.

The application relates to the technical field of aspirin pharmaceutical chemistry, in particular to an aspirin-sulfonamide hybrid, a preparation method and application thereof. The preparation method can synthesize a plurality of novel aspirin-sulfonamide hybrids by taking piperazine as a bridge, and by a three-step continuous method of "acyl chlorination, sulfonamidation and N-acylation" according to a "molecular hybridization principle". In the process, only one separation and purification is performed, and the preparation steps are simple. The aspirin-sulfonamide hybrid prepared by the method is most effective on human non-small cell lung cancer cells A549, and the activity is more than 33 times higher than that of a parent aspirin, and is similar to the activity of an anticancer drug irinotecan. The aspirin-sulfonamide hybrid 3k prepared by the method has a certain inhibitory effect on various cancer cells. The hybrid can induce human non-small cell lung cancer A549 cell apoptosis in a concentration-dependent manner, and can induce human non-small cell lung cancer A549 cell cycle arrest in the G0 / G1 phase, and inhibit cell growth.

The invention discloses a cyclic iridium-ester tin imidazo phenanthroline complex with an aggregation-induced emission (AIE) characteristic as well as a preparation method and an anti-cancer application of the cyclic iridium-ester tin imidazo phenanthroline complex. The structural formula is as shown in formula (I), R1 is phenyl or 3-pyridyl, and R2 is hydrogen or fluorine. By testing the growth inhibition rate of the target compound on human alveolar basal epithelial cancer cells (A549) and comparing, the target compound shows potential A549 cell proliferation inhibition activity. In addition, the target complex shows a unique AIE luminescence characteristic, and is accumulated in lysosome of A549 cells, resulting in lysosome damage and apoptosis.

The present invention discloses a semicarbazide derivative and its preparation method and application, which belongs to the technical field of anti-lung cancer targeted drugs. The semicarbazide derivative of the present invention can inhibit the growth of H1299 cells in a dose-dependent manner, but has little toxicity to normal lung epithelial cells BEAS-2B. The semicarbazide derivative of the present invention can significantly inhibit the cloning of non-small cell lung cancer cells A549 and H1299, so it has a significant inhibitory effect on the proliferation of non-small cell lung cancer. The semicarbazide derivative provided by the present invention can inhibit the protein expression of GPX4 in non-small cell lung cancer A549 cells, and by inhibiting the protein expression of GPX4, promote the ferroptosis of non-small cell lung cancer cells, thereby playing a role in suppressing tumors.

The ranitidine hydrochloride causes the change of multiple vesicles of A549 cells. The invention relates to the technical field of drug ranitidine hydrochloride, and the drug ranitidine hydrochloride is found to have the effect of causing the change of multiple vesicles of cells for the first time, and mainly can cause the change of multiple vesicles of A549 cells. The technical problem to be solved is that ranitidine hydrochloride is utilized to treat A549 cells, and treatment conditions are changed to observe whether the drug can change the morphological structure of the A549 cells or not. The key point of the technical scheme for solving the problem is that after ranitidine hydrochloride with the concentration of 2.39 mmol / L, 4.78 mmol / L or 7.17 mmol / L is used for treating A549 cells for 24 hours, the morphological structure change of the cells is observed through a microscope. The main application is as follows: when ranitidine hydrochloride with the concentration of 4.78 or 7.17 mmol / L is used for treating A549 cells for 24 hours, remarkable multi-vesicle change can be triggered. After the drug with the concentration of 4.78 mmol / L causes the change of the multiple vesicles of the cells, the multiple vesicles disappear after being cultured in a culture solution without the drug for 24 hours. The medicine can be utilized to trigger the phenomena of the change of the multiple vesicles and the disappearance process of the multiple vesicles of the cells, the ultrastructure and the molecular mechanism formed by the vesicles are further researched, and the deep understanding of the formation and disappearance mechanism of the vesicles is facilitated.